PM
LBPH

Prosight Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Prosight Management’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-321,154
Closed -$1.79M – 50
2023
Q3 		$1.79M Sell
321,154
-413,743
-56% -$2.66M 0.57% 33
2023
Q2 		$5.39M Sell
734,897
-165,703
-18% -$1.25M 1.58% 21
2023
Q1 		$3.61M Buy
+900,600
New +$4.4M 1.71% 25

Other funds holding LBPH

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management's LBPH Position: Q4 2023 in Review

Prosight Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2023, closing a stake of 321,154 shares — an estimated $1.79M sold.

Prosight Management first reported a position in LBPH in Q1 2023 and held it in 3 quarters. The position peaked at $5.39M in Q2 2023. 52 funds tracked by Wall St. Rank hold LBPH as of Q4 2023.

  • Prosight Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Prosight Management sold 321,154 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $1.79M.
  • Prosight Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • Prosight Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $5.39M in Q2 2023.
  • 52 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Prosight Management's 13F filing for Q4 2023, filed 14 Feb 2024.